


All women diagnosed with early breast cancer are at risk of recurrence



- The greatest risk of disease recurrence is around 18 months after surgery, and this high level of risk remains for around 5 years after surgery.¹
- There is a prominent early peak of recurrences in the absence of adjuvant treatment such as Arimidex (anastrozole). Arimidex has been shown to substantially reduce this early peak compared with tamoxifen.
- For the vast majority of patients whose cancer recurs, their disease is incurable.
- The primary goal of treatment is to prevent all types of recurrence, which is imperative to saving lives.
- A treatment that is more tolerable than tamoxifen and more effective at reducing the risk of all recurrences, like Arimidex, is therefore desirable.

1. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. *J Clin Oncol.* 1996;**14**(10):2738-46

Adapted from EBCTCG Meta-Analysis, *Lancet* 1998;352:930-942

● Control (untreated patients)